RET and thyroid gland carcinoma: LIBRETTO-001 clinical trial (ClinicalTrials.gov, Identifier NCT03157128) (59) enrolled 531 patients of whom 162 with RET-mutant thyroid cancers, between May 2017 and June 2019.